摘要
目的研究治疗脑血管缺氧疾病的创新载氧药物，其最主要功能是能够向缺氧组织有效地供氧。恢复无基质血红蛋白的供氧能力是开发载氧药物的关键步骤。双（3，5-二溴水杨基）延胡索酸脂（bis（3，5．dibromosalicyl）fumarate，DBBF）交联修饰血红蛋白α链的工艺研究，是为开发具有合适亲氧性的载氧药物奠定基础。方法电泳和HPLC检测聚合程度，在生理条件下检测其生物活性和P50（血红蛋白到达氧半饱和态所对应的氧分压）。结果DBBF有效地交联血红蛋白（hemoglobin，Hb），既恢复了无基质血红蛋白（stroma-free hemoglobin，SFHb）的P50，又增加了血红蛋白四聚体的稳定性，很好地保持了血红蛋白的生物活性。结论DBBF-αHb作为开发具有合适亲氧性的载氧药物的第一步，为后续工作奠定了基础。
Objective Oxygen-carrying drug is an irmovative finding for curing ischemia cerebral and heart disease. The critical feature of that is to have appropriate capacity of oxygen-carrying and oxygen-unloading. The cross-linking reaction of human placenta hemoglobin （Hb） with bis （3, 5-dibromosalicyl） fumarate （DBBF）, leading to DBBF-αHb, is the key step toward the synthesis of a potential oxygen carrying drug. Methods The degree of polymerization of Hb was detected with SDS-PAGE and HPLC. Under the physiological conditions, the P50 （the oxygen pressure representing 50% saturation of hemoglobin with oxygen） and the biological activity of modified Hb were measured. Results The hemoglobin was greatly stabilized after it was cross-linked with DBBF. The DBBF cross-linking effectively elevated Ps0 in the Hb. In the meanwhile, The DBBF-αHb well reserved the biological activity of Hb. Conclusion The results showed that the cross linking technique of Human Placenta Hemoglobin with DBBF established in this study could be a well basics for further synthesis of a potential oxygen carrying drug.
出处
《国际生物医学工程杂志》
CAS
2007年第2期70-72,共3页
International Journal of Biomedical Engineering
